You are here
Home 🌿 Medical Cannabis News 🌿 Research Shows Marijuana Can Reduce Side Effects of Multiple Sclerosis 🌿Research Shows Marijuana Can Reduce Side Effects of Multiple Sclerosis
Research shows medical marijuana can reduce the side effects of multiple sclerosis (MS) and provide relief to those suffering from this illness. MS is an autoimmune disease and progressive neurodegenerative condition. It affects the nervous system, which gradually impacts the entire body.
According to the Multiple Sclerosis Foundation, half a million people in the United States have been diagnosed with MS. And according to the National Multiple Sclerosis Society, women are diagnosed with MS at lease twice as often as men, usually between the ages of 20 – 50.
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
420 Intel is Your Source for Marijuana News
420 Intel Canada is your leading news source for the Canadian cannabis industry. Get the latest updates on Canadian cannabis stocks and developments on how Canada continues to be a major player in the worldwide recreational and medical cannabis industry.
420 Intel Canada is the Canadian Industry news outlet that will keep you updated on how these Canadian developments in recreational and medical marijuana will impact the country and the world. Our commitment is to bring you the most important cannabis news stories from across Canada every day of the week.
Marijuana industry news is a constant endeavor with new developments each day. For marijuana news across the True North, 420 Intel Canada promises to bring you quality, Canadian, cannabis industry news.
You can get 420 Intel news delivered directly to your inbox by signing up for our daily marijuana news, ensuring you’re always kept up to date on the ever-changing cannabis industry. To stay even better informed about marijuana legalization news follow us on Twitter, Facebook and LinkedIn.